Treating Post-inflammatory hyperpigmentation with a tyrosinase-inhibitor
Agneta Troilius Rubin, MD, PhD, is an Associate Professor in Dermatology, Malmö, Sweden; Zoi...
Read MoreAgneta Troilius Rubin, MD, PhD, is an Associate Professor in Dermatology, Malmö, Sweden; Zoi...
Read MoreDr Jennifer David discusses the use of cysteamine 5% as a novel first line non‑hydroquinone...
Read MoreCase Study | 0
Leonardo Marini, MD, PhD, discusses two recent cases of treating melasma in female patients with a new 5% cysteamine topical formulation Afortunate woman craves nothing but a good anti‑depressant cream,...
Read MoreSabine Zenker provides a review of the treatment principles for melasma using bleaching topicals...
Read MoreDr Sandeep Cliff and Nikita Cliff-Patel consider the triggers, diagnosis and current treatment options for melasma based on a review of the available literature Melasma is a chronic acquired condition...
Read MoreScientis Pharma, a leading dermatology research company based in Geneva, Switzerland, has released the world’s first cysteamine-based cream to treat hyperpigmentation disorders. Cysteamine Cream® is a novel, super potent skin...
Read MoreChytra Anand reviews the combinational treatment options available for melasma, including topical therapies, chemical peels, and lasers. Melasma is a term derived from the Greek word ‘melas’ meaning black ....
Read MoreAndreas Katsambas and Clio Dessinioti discuss the options available for treating melasma, including bleaching agents, combination formulas, and laser therapy
Read More